SAN DIEGO , Oct. 27, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces the appointment of David
SAN DIEGO , Oct. 31, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release
Revenues increased 58% sequentially to a record highCommercial sample volume more than doubled versus prior year period9 consecutive quarters of growth in total sample volumeCompany to host conference call at 4:30 p.m. Eastern time today
SAN DIEGO , Nov. 21, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that President and CEO
Results demonstrate high level of analytical sensitivity and specificity for the Company's non-invasive, clinically actionable biomarker test for immunotherapy
High concordance of the Company's Target-Selector™ platform enables real-time monitoring of key biomarkers in metastatic breast cancer, and provides an alternative when tissue biopsy is not an option
Study designed to address the significant medical need for rapidly and accurately diagnosing brain metastases in breast cancer patients to enable better treatment decisions
Biocept further expands its global patent estate for capturing and detecting cells that are in very low abundance and that can provide important molecular information from biological fluids
SAN DIEGO , Feb. 6, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the management of cancer patients, announces that President and CEO Michael W. Nall will present a corporate overview at the 19 th
